“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
A method using augmented reality to create accurate visual representations of ionizing radiation, developed at ORNL, has been licensed by Teletrix, a firm that creates advanced simulation tools to train the nation’s radiation control workforce.
Oak Ridge National Laboratory physicist Elizabeth “Libby” Johnson (1921-1996), one of the world’s first nuclear reactor operators, standardized the field of criticality safety with peers from ORNL and Los Alamos National Laboratory.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.